{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002480","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.305601+00:00","generated_at":"2026-06-16T19:10:10.372221+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Compass Therapeutics appoints Richard S. Lindahl to Board and Audit Committee chair","bullets":["Richard S. Lindahl appointed as Class III director effective April 21, 2023; term expires at 2023 annual meeting.","Also appointed chairman of Audit Committee; qualifies as independent director and audit committee financial expert.","Compensation: $45,000 cash retainer, $10,000 additional for Audit Committee chair; 50,000 share option award vesting monthly over four years.","No family relationships or reportable transactions with the Company or its officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002480","json":"https://secwatch.observer/filing/0001171843-23-002480.json","markdown":"https://secwatch.observer/filing/0001171843-23-002480.md","text":"https://secwatch.observer/filing/0001171843-23-002480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/0001171843-23-002480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/f8k_042423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T19:10:10.372221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ae5e0dabb","claim":"Richard S. Lindahl was appointed as Class III Director at Compass Therapeutics, Inc..","evidence_excerpt":"On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/0001171843-23-002480-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}